Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma

Agarwal Suresh K.; Salem Ahmed Hamed; Danilov Alexey V.; Hu Beibei; Puvvada Soham; Gutierrez Martin; Chien David; Lewis Lionel D.; Wong Shekman L.

首页> 外文期刊>British Journal of Clinical Pharmacology >Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma

【24h】

Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma

机译：强大的CYP3A抑制剂酮康唑抑制剂对非霍奇金淋巴瘤患者威尼妥（BCL-2抑制剂）的药代动力学

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimsTo examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole, on the pharmacokinetics, safety and tolerability of venetoclax.

机译：Aimsto检测强细胞色素P450（CYP）3A抑制剂，酮康唑对威妥脲的药代动力学，安全性和耐受性的影响。

著录项

来源
《British Journal of Clinical Pharmacology》 |2017年第4期|共9页
作者
Agarwal Suresh K.; Salem Ahmed Hamed; Danilov Alexey V.; Hu Beibei; Puvvada Soham; Gutierrez Martin; Chien David; Lewis Lionel D.; Wong Shekman L.;
展开▼
作者单位

AbbVie Inc Clin Pharmacol &

Pharmacometr Dept R4PK Bldg AP31-3 1 North Waukegan Rd N Chicago IL;

AbbVie Inc Clin Pharmacol &

Pharmacometr Dept R4PK Bldg AP31-3 1 North Waukegan Rd N Chicago IL;

Geisel Sch Med Dartmouth Dept Med Lebanon NH USA;

AbbVie Inc Clin Pharmacol &

Pharmacometr Dept R4PK Bldg AP31-3 1 North Waukegan Rd N Chicago IL;

Univ Arizona Ctr Canc Tucson AZ USA;

Hackensack Univ Med Ctr Ctr Canc Hackensack NJ USA;

AbbVie Inc Oncol Dev N Chicago IL USA;

Geisel Sch Med Dartmouth Dept Med Lebanon NH USA;

AbbVie Inc Clin Pharmacol &

Pharmacometr Dept R4PK Bldg AP31-3 1 North Waukegan Rd N Chicago IL;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
BCL-2; drug-drug interaction; ketoconazole; pharmacokinetics; venetoclax;

机译：Bcl-2;药物 - 药物相互作用;酮康唑;药代动力学;威尼妥罗克斯;

相似文献

外文文献
中文文献
专利

1. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma [J] . Agarwal Suresh K., Salem Ahmed Hamed, Danilov Alexey V., British Journal of Clinical Pharmacology . 2017,第4期

机译：强大的CYP3A抑制剂酮康唑抑制剂对非霍奇金淋巴瘤患者威尼妥（BCL-2抑制剂）的药代动力学
2. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients. [J] . Ahmed Hamed Salem, Jianning Yang, Alison Graham, Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第4期

机译：酮康唑共同施用强大的CYP3A抑制剂，对Navitoclax的药代动力学，安全性和耐受性，癌症患者癌症患者的一流的口服BCL-2家族抑制剂。
3. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients. [J] . Ahmed Hamed Salem, Jianning Yang, Alison Graham, Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第4期

机译：酮康唑（一种强CYP3A抑制剂）的共同给药对癌症患者中一流的口服Bcl-2家族抑制剂navitoclax的药代动力学，安全性和耐受性的影响。
4. Development of a HPLC-MS/MS assay to measure the novel angiogenesis inhibitor E-3810 in plasma. Preliminary pharmacokinetic evaluation in cancer patients [C] . Federica Sala, Valeria Livi, Roberta Cereda, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：培养HPLC-MS / MS测定以测量血浆中的新型血管生成抑制剂E-3810。癌症患者的初步药代动力学评估
5. Fluorescence in situ hybridization (FISH) and risk factors for non-Hodgkin lymphoma (NHL) subtypes defined by t(14;18) translocations and bcl-2 expression. [D] . Chang, Cindy Ma. 2007

机译：荧光原位杂交（FISH）和非霍奇金淋巴瘤（NHL）亚型的危险因素，定义为t（14; 18）易位和bcl-2表达。
6. Effect of ketoconazole a strong CYP3A inhibitor on the pharmacokinetics of venetoclax a BCL‐2 inhibitor in patients with non‐Hodgkin lymphoma [O] . Suresh K. Agarwal, Ahmed Hamed Salem, Alexey V. Danilov, 2017

机译：酮康唑（一种强CYP3A抑制剂）对非霍奇金淋巴瘤患者Venetoclax（一种BCL-2抑制剂）的药代动力学的影响
7. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers [O] . Meera Tugnait, Neeraj Gupta, Michael J. Hanley, 2019

机译：强CYP2C8或CYP3A抑制和CYP3A诱导对Brigatinib的药代动力学，口腔血管性淋巴瘤激酶抑制剂，健康志愿者的影响

Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma

摘要

著录项

相似文献

相关主题

期刊订阅